News & Updates

The thrombopoietin-receptor agonist romiplostim helps mitigate chemotherapy-induced thrombocytopenia, reducing related treatment modifications in patients with gastrointestinal cancers, as shown in the landmark phase III RECITE trial.

Immunotherapy (IO) has shifted the management of resectable non-small-cell lung cancer (NSCLC) towards a multimodality approach that deepens treatment response, resulting in meaningful gains in event‑free survival (EFS) and overall survival (OS). At an industry-sponsored symposium during the 33^rd Annual Scientific Meeting of the Hong Kong College of Radiologists, experts discussed the evidence supporting standard-of-care (SoC) neoadjuvant and perioperative IO in patients with resectable NSCLC, as well as the crucial role of multidisciplinary teams (MDTs) in optimizing treatment outcomes in this population.

The presence of reflux disease, no matter the type, appears to elevate the risk for colonic neoplasia, suggests a recent study.

New drug applications approved by US FDA as of 16-31 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In lung cancer patients receiving immune checkpoint inhibitors (ICIs), survival is not necessarily better when treatment is administered in the morning vs in the afternoon, according to the i-TIMES study.

The 9-valent HPV vaccine helps prevent HPV-related cancers in adolescents and young adult males, as shown in a retrospective study.

A recent study has found a higher prevalence of falls and fractures in prostate cancer patients receiving enzalutamide relative to those reported in previous clinical trials and postmarketing research.